My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Pramipexole (SND-919)
    Pramipexole (SND-919)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0046
    CAS #: 104632-26-0Purity ≥98%

    Description: Pramipexole (also known as SND 919), an agonist of the Gαi-linked dopamine receptors D2, D3, and D4, is a potent dopamine agonist of the non-ergoline class. It is used for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptor. Pramipexole is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively.

    References: Clin Ther. 2006 Aug;28(8):1065-78.

    Related CAS: 191217-81-9 (Pramipexole 2HCl Monohydrate); 104632-25-9 (HCl) 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)211.33
    CAS No.104632-26-0
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 42 mg/mL (198.7 mM)
    Water: <1 mg/mL
    Ethanol: 42 mg/mL (198.7 mM) 
    Other info
    Chemical Name: (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
    SMILES Code: CCCN[[email protected]](C1)CCC2=C1SC(N)=N2 
    SynonymsSND 919; SND-919; SND919; Pramipexole; Oprymea; Pramipexol; Pramipexolum

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Pramipexole, a chemically novel dopamine agonist used for the treatment of Parkinson's disease symptoms, possesses antioxidant activity and is neuroprotective toward substantia nigral dopamine neurons in hypoxic-ischemic and methamphetamine models. Pramipexole reduces the levels of oxygen radicals produced by methylpyridinium ion (MPP+) both when incubated with SH-SY5Y cells and when perfused into rat striatum. Pramipexole also exhibits a concentration-dependent inhibition of opening of the mitochondrial transition pore induced by calcium and phosphate or MPP+. Pramipexole decreases the levels of dopamine metabolites dose dependently, whereas striatal dopamine levels remains unchanged. Pramipexole acts in both of these models to reduce the elevated dopamine turnover and the associated elevation in hydroxyl radical production secondary to increased MAO activity that could be responsible for oxidative damage to the nigrostriatal neurons. Pramipexole (4-100 mM) significantly attenuates DA- or L-DOPA-induced cytotoxicity and apoptosis, an action which is not blocked by D3 antagonist U-99194 A or D2 antagonist raclopride. Pramipexole also protects MES 23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. Pramipexole can effectively inhibit the formation of melanin, an end product resulting from DA or L-DOPA oxidation in cell-free system.

    In VivoPramipexole (0.001-1 mg/kg s.c.) reduces exploratory locomotor activity in mice. Pramipexole (1 mg/kg, p.o.) is able to significantly reduce the increased DA turnover, but by only 16%. 
    Animal model Mice
    Formulation & Dosage 0.001-1 mg/kg s.c.; 1 mg/kg, p.o.
    ReferencesJ Neurochem. 1998 Jul;71(1):295-301; Eur J Pharmacol. 1992 May 14;215(2-3):161-70. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    An external file that holds a picture, illustration, etc. Object name is nihms692427f2.jpg

    Effect Size of Neurocognitive Change by Treatment Group (All Completers). J Clin Psychiatry. 2012 Jan; 73(1): 103–112.

    An external file that holds a picture, illustration, etc. Object name is nihms692427f3.jpg

    Effect Size of Neurocognitive Change by Treatment Group (Euthymic Subgroup). J Clin Psychiatry. 2012 Jan; 73(1): 103–112.

    An external file that holds a picture, illustration, etc. Object name is nihms692427f4.jpg

    Enhanced Effect Size Change in the Euthymic Subgroup Treated with Pramipexole. J Clin Psychiatry. 2012 Jan; 73(1): 103–112.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?